283 related articles for article (PubMed ID: 34011561)
1. Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
Miao YR; Thakkar KN; Qian J; Kariolis MS; Huang W; Nandagopal S; Yang TTC; Diep AN; Cherf GM; Xu Y; Moon EJ; Xiao Y; Alemany H; Li T; Yu W; Wei B; Rankin EB; Giaccia AJ
Clin Cancer Res; 2021 Aug; 27(15):4435-4448. PubMed ID: 34011561
[TBL] [Abstract][Full Text] [Related]
2. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers.
Zhu L; Liu J; Chen J; Zhou Q
J Hematol Oncol; 2021 Dec; 14(1):206. PubMed ID: 34930377
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
4. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Chin CD; Fares CM; Konecny GE; Rao J
Curr Opin Obstet Gynecol; 2020 Feb; 32(1):84-90. PubMed ID: 31804230
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities.
Peng Z; Li M; Li H; Gao Q
Drug Discov Today; 2023 Aug; 28(8):103666. PubMed ID: 37302543
[TBL] [Abstract][Full Text] [Related]
7. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
8. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
9. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
Front Immunol; 2018; 9():2560. PubMed ID: 30559738
[TBL] [Abstract][Full Text] [Related]
10. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H
Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547
[TBL] [Abstract][Full Text] [Related]
11. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
12. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
[No Abstract] [Full Text] [Related]
13. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
14. Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer.
Felices M; Wesley E; Bendzick LE; Kodal B; Hopps R; Grzywacz B; Hinderlie P; Miller JS; Geller MA
Cancer Immunol Res; 2023 May; 11(5):674-686. PubMed ID: 36807510
[TBL] [Abstract][Full Text] [Related]
15. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
16. The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.
Bowen RC; Lawson BM; Jody NM; Potter HD; Lucarelli MJ
Ophthalmic Plast Reconstr Surg; 2020; 36(1):74-79. PubMed ID: 31593039
[TBL] [Abstract][Full Text] [Related]
17. The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.
Fan Z; Wu C; Chen M; Jiang Y; Wu Y; Mao R; Fan Y
Acta Pharm Sin B; 2022 Mar; 12(3):1041-1053. PubMed ID: 35530130
[TBL] [Abstract][Full Text] [Related]
18. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
van Dam LS; de Zwart VM; Meyer-Wentrup FA
Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Devereaux KA; Charu V; Zhao S; Charville GW; Bangs CD; van de Rijn M; Cherry AM; Natkunam Y
Hum Pathol; 2018 Dec; 82():39-45. PubMed ID: 30539796
[TBL] [Abstract][Full Text] [Related]
20. High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
Li Y; Liang Z; Tian Y; Cai W; Weng Z; Chen L; Zhang H; Bao Y; Zheng H; Zeng S; Bei C; Li Y
Cancer Sci; 2018 Aug; 109(8):2435-2445. PubMed ID: 29890018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
